>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
胰高血糖素样肽-1的研究进展
作者:王璠璠  卢海英  刘莉洁 
单位:东南大学 医学院,江苏 南京 210009
关键词:胰高血糖素样肽-1 肠促胰岛素 β细胞 2型糖尿病 综述 
分类号:R333.3;R587.1
出版年·卷·期(页码):2014·33·第二期(200-206)
摘要:

胰高血糖素样肽-1(glucagon like peptide-1,GLP-1)是肠L细胞以营养依赖性方式分泌的一种具有葡萄糖依赖性促胰岛素分泌功能的肠促胰岛素,它还可通过促进β细胞增殖与分化、抑制β细胞凋亡、抑制胰高血糖素分泌、抑制胃肠蠕动等方式实现其血糖调节效应,因而已成为2型糖尿病发病机制及药物治疗中的研究热点。作者对近年GLP-1的生物学研究进展进行综述。

参考文献:

[1] BAYLISS W M,STARLING E H.The mechanism of pancreatic secretion[J].J Physiol,1902,28(5):325-353.
[2] CREUTZFELDT W.The-]history of the incretin concept[J].Regul Pept,2005,128(2):87-91.
[3] La BARRE J,STILL E U.Studies on the physiology of secretin Ⅲ.Further studies on the effects of secretin on the blood sugar[J].Am J Physiol,1930,91(2):649-653.
[4] MCINTYRE N,HOLDSWORTH C,TURNER D.New interpretation of oral glucose tolerance[J].Lancet,1964,2(7349):20.
[5] ELRICK H,STIMMLER L,HLAD C,et al.Plasma insulin response to oral and intravenous glucose administration[J].J Clin Endocrinol Metab,1964,24(10):1076-1082.
[6] PERLEY M J,KIPNIS D M.Plasma insulin responses to oral and intravenous glucose:studies in normal and Diabetic subjects[J].J Clin Invest,1967,46(12):1954.
[7] YALOW R S,BERSON S A.Immunoassay of endogenous plasma insulin in man[J].J Clin Invest,1960,39:1157-1175.
[8] UNGER R H,EISENTRAUT A M.Entero-insular axis[J].Arch Intern Med,1969,123(3):261-266.
[9] CREUTZFELDT W.The incretin concept today[J].Diabetologia,1979,16(2):75-85.
[10] BROWN J,MUTT V,PEDERSON R.Further purification of a polypeptide demonstrating enterogastrone activity[J].J Physiol,1970,209(1):57.
[11] BROWN J C,DRYBURGH J R.A gastric inhibitory polypeptide Ⅱ:the complete amino acid sequence[J].Can J Biochem,1971,49(8):867-872.
[12] PEDERSON R A,BROWN J C.Inhibition of histamine-,pentagastrin-,and insulin-stimulated canine gastric secretion by pure "gastric inhibitory polypeptide"[J].Gastroenterology,1972,62(3):393.
[13] SCHMIDT W,SIEGEL E,CREUTZFELDT W.Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets[J].Diabetologia,1985,28(9):704-707.
[14] BAGGIO L L,DRUCKER D J.Biology of incretins:GLP-1 and GIP[J].Gastroenterology,2007,132(6):2131-2157.
[15] WHITE J W,SAUNDERS G F.Structure of the human glucagon gene[J].Nucl Acids Res,1986,14(12):4719-4730.
[16] FEHMANN H C,GOKE R,GOKE B.Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide[J].Endocr Rev,1995,16(3):390-410.
[17] GAUTIER J F,FETITA S,SOBNGWI E,et al.Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes[J].Diabetes Metab,2005,31(3 Pt 1):233-242.
[18] HOLST J J.The physiology of glucagon-like peptide 1[J].Physiol Rev,2007,87(4):1409-1439.
[19] EISSELE R,GKE R,WILLEMER S,et al.Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat,pig and man[J].Eur J Clin Invest,1992,22(4):283-291.
[20] DRUCKER D J.Glucagon-like peptides[J].Diabetes,1998,47(2):159-169.
[21] ELLIOTT R M,MORGAN L M,TREDGER J A,et al.Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man:acute post-prandial and 24-h secretion patterns[J].J Endocrinol,1993,138(1):159-166.
[22] DRUCKER D J.Minireview:the glucagon-like peptides[J].Endocrinology,2001,142(2):521-527.
[23] MENTLEIN R,GALLWITZ B,SCHMIDT W E.Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide,glucagon-like peptide-1(7-36)amide,peptide histidine methionine and is responsible for their degradation in human serum[J].Eur J Biochem,1993,214(3):829-835.
[24] RUIZ-GRANDE C,ALARCON C,ALCANTARA A,et al.Renal catabolism of truncated glucagon-like peptide 1[J].Horm Metab Res,1993,25(12):612-616.
[25] WHEELER M B,LU M,DILLON J S,et al.Functional expression of the rat glucagon-like peptide-I receptor,evidence for coupling to both adenylyl cyclase and phospholipase-C[J].Endocrinology,1993,133(1):57-62.
[26] 何珂,胡蕴,毛晓明.TCF7L2基因与2型糖尿病发生相关性的研究进展[J].现代医学,2013,41(2):140-143.
[27] WEI Y,MOJSOV S.Tissue-specific expression of the human receptor for glucagon-like peptide-I:brain,heart and pancreatic forms have the same deduced amino acid sequences[J].FEBS Lett,1995,358(3):219-224.
[28] DUNPHY J L,TAYLOR R G,FULLER P J.Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression[J].Mol Cell Endocrinol,1998,141(1-2):179-186.
[29] NAUCK M A.Is glucagon-like peptide 1 an incretin hormone?[J].Diabetologia,1999,42(3):373-379.
[30] LIGHT P E,MANNING-FOX J E,RIEDEL M J,et al.Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A-and ADP-dependent mechanism[J].Mol Endocrinol,2002,16(9):2135-2144.
[31] HOLZ G G T,KUHTREIBER W M,HABENER J F.Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)[J].Nature,1993,361(6410):362-365.
[32] QUALMANN C,NAUCK M A,HOLST J J,et al.Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1)-36 amide]in the fasting state in healthy subjects[J].Acta Diabetologica,1995,32(1):13-16.
[33] HANSOTIA T,DRUCKER D J.GIP and GLP-1 as incretin hormones:lessons from single and double incretin receptor knockout mice[J].Regul Pept,2005,128(2):125-134.
[34] YANG S,FRANSSON U,FAGERHUS L,et al.Enhanced cAMP protein kinase A signaling determines improved insulin secretion in a clonal insulin-producing beta-cell line (INS-1 832/13)[J].Mol Endocrinol,2004,18(9):2312-2320.
[35] HOLST J J,GROMADA J.Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans[J].Am J Physiol Endocrinol Metab,2004,287(2):E199-206.
[36] LI Y,CAO X,LI L X,et al.beta-Cell Pdx1 expression is essential for the glucoregulatory,proliferative,and cytoprotective actions of glucagon-like peptide-1[J].Diabetes,2005,54(2):482-491.
[37] DRUCKER D J,PHILIPPE J,MOJSOV S,et al.Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line[J].Proc Nat Acad Sci USA,1987,84(10):3434-3438.
[38] LI Y,CAO X,LI L X,et al.β-Cell Pdx1 expression is essential for the glucoregulatory,proliferative,and cytoprotective actions of glucagon-like peptide-1[J].Diabetes,2005,54(2):482-491.
[39] BREGENHOLT S,MLDRUP A,BLUME N,et al.The long-acting glucagon-like peptide-1 analogue,liraglutide,inhibits β-cell apoptosis in vitro[J].Biochem Biophys Res Commun,2005,330(2):577-584.
[40] YUSTA B,BAGGIO L L,ESTALL J L,et al.GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress[J].Cell Metab,2006,4(5):391-406.
[41] FARILLA L,HUI H,BERTOLOTTO C,et al.Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats[J].Endocrinology,2002,143(11):4397-4408.
[42] FARILLA L,BULOTTA A,HIRSHBERG B,et al.Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets[J].Endocrinology,2003,144(12):5149-5158.
[43] DRUCKER D J.Glucagon-like peptides:regulators of cell proliferation,differentiation,and apoptosis[J].Mol Endocrinol,2003,17(2):161-171.
[44] STOFFERS D A,KIEFFER T J,HUSSAIN M A,et al.Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas[J].Diabetes,2000,49(5):741-748.
[45] BULOTTA A,HUI H,ANASTASI E,et al.Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1[J].J Mol Endocrinol,2002,29(3):347-360.
[46] FARILLA L,BULOTTA A,HIRSHBERG B,et al.Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets[J].Endocrinology,2003,144(12):5149-5158.
[47] LI Y,HANSOTIA T,YUSTA B,et al.Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis[J].J Biol Chem,2003,278(1):471-478.
[48] MIAO X Y,GU Z Y,LIU P,et al.The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPKmTORP70S6K signaling pathway[J].Peptides,2013,39:71-79.
[49] D'ALESSIO D A,FUJIMOTO W Y,ENSINCK J W.Effects of glucagonlike peptide I-(7-36) on release of insulin,glucagon,and somatostatin by rat pancreatic islet cell monolayer cultures[J].Diabetes,1989,38(12):1534-1538.
[50] SAMOLS E,BONNER-WEIR S,WEIR G C.Intra-islet insulin-glucagon-somatostatin relationships[J].Clin Endocrinol Metab,1986,15(1):33-58.
[51] MACDONALD P E,EL-KHOLY W,RIEDEL M J,et al.The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion[J].Diabetes,2002,51 (Suppl 3):S434-442.
[52] MEIER J J,KEMMERIES G,HOLST J J,et al.Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects[J].Diabetes,2005,54(7):2212-2218.
[53] HOLST J J.Gut hormones as pharmaceuticals.From enteroglucagon to GLP-1 and GLP-2[J].Regul Pept,2000,93(1-3):45.
[54] NSLUND E,BARKELING B,KING N,et al.Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men[J].Int J Obes Relat Metab Disord,1999,23(3):304-311.
[55] GUTZWILLER J P,DREWE J,GOKE B,et al.Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2[J].Am J Physiol,1999,276(5 Pt 2):R1541-1544.
[56] HOLST J J.The physiology of glucagon-like peptide 1[J].Physiol Rev,2007,87(4):1409-1439.
[57] SCROCCHI L A,BROWN T J,MACLUSKY N,et al.Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene[J].Nat Med,1996,2(11):1254-1258.
[58] BALKAN B,LI X.Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms[J].Am J Physiol Regul Integr Comp Physiol,2000,279(4):R1449-1454.
[59] KNAUF C,CANI P D,PERRIN C,et al.Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage[J].J Clin Invest,2005,115(12):3554-3563.
[60] SANDOVAL D.CNS GLP-1 regulation of peripheral glucose homeostasis[J].Physiol Behav,2008,94(5):670-674.
[61] BARRAGAN J M,RODRIGUEZ R E,BLAZQUEZ E.Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats[J].Am J Physiol,1994,266(3 Pt 1):E459-466.
[62] NIKOLAIDIS L A,ELAHI D,HENTOSZ T,et al.Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy[J].Circulation,2004,110(8):955-961.
[63] FONTANA J,CERVINKOVA Z,ANDEL M.Effects of GLP-1 (glucagon-like peptide 1) on liver[J].Vnitrni Lekarstvi,2013,59(7):551-558.
[64] BENITO E,BLAZQUEZ E,BOSCH M A.Glucagon-like peptide-1-(7-36)amide increases pulmonary surfactant secretion through a cyclic adenosine 3',5'-monophosphate-dependent protein kinase mechanism in rat type II pneumocytes[J].Endocrinology,1998,139(5):2363-2368.
[65] GUTZWILLER J P,TSCHOPP S,BOCK A,et al.Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men[J].J Clin Endocrinol Metab,2004,89(6):3055-3061.
[66] BRIONES M,BAJAJ M.Exenatide:a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus[J].Expert Opin Pharmacother,2006,7(8):1055-1064.
[67] DRUCKER D J,DRITSELIS A,KIRKPATRICK P.Liraglutide[J].Nat Rev Drug Discov,2010,9(4):267-268.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 405708 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-83272481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364